STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2021

May 25, 2021

==> picture [136 x 45] intentionally omitted <==

May 25, 2021

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051.

Scrip code: STAR

Dear Madam/ Sir,

Ref: Company’s press release of March 19, 2021 titled “ Stelis concludes US$ 195m Series B and Series C fund raise - Significant interest from marquee long term.

Sub: Disclosure under Regulation 30 of SEBI Listing Regulations

This has reference to the Company’s press release referred above.

We now wish to inform you that Stelis has completed the Series C round fund raising of USD 125 Million (including secondary placement of USD 40 Million) from marquee long term investors led by TPG Growth followed by other long-term investors namely, Route One, Think Investments and the Mankekar Family.

The funds will be used by Stelis for:

• (a) Completion of last mile capex for the CDMO business including setting up of 6KL mammalian block, ramp up of process development lab and other technical capabilities;

• (b) Accelerating the vaccine block infrastructure with ability to cater to multiple vaccine types including viral vector, protein subunit, RNA and DNA;

• (c) Debt servicing and other general corporate purposes.

Consequent to the above transaction, Strides stake in Stelis now stands at 37.09% against 54.48% prior to the Series C funding.

Thanks & Regards,

For Strides Pharma Science Limited,

==> picture [114 x 47] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [84 x 83] intentionally omitted <==

==> picture [479 x 52] intentionally omitted <==